Status:
COMPLETED
Study of Adverse Renal Effects of Immune Checkpoints Inhibitors
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Adverse Effect
Renal Toxicity
Eligibility:
All Genders
18+ years
Brief Summary
Renal toxic events related to Immune Checkpoints Inhibitors therapy (Nivolumab, Pembrolizumab, Atezolizumab and Ipilimumab) have been recently reported. These were immune-allergic acute interstitial n...
Eligibility Criteria
Inclusion
- All patients treated by one of the Immune Checkpoints inhibitors (Nivolumab, Pembrolizumab, ipilimumab or Atezolizumab), for neoplastic pathology in dermatologic, pneumologic, or medical oncology department.
Exclusion
- Minor patients (less than 18y).
- Refusal to consent.
- For statistical analysis: Acute Renal Failure caused by another identified etiology than drug toxicity.
Key Trial Info
Start Date :
October 27 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 27 2017
Estimated Enrollment :
353 Patients enrolled
Trial Details
Trial ID
NCT03316417
Start Date
October 27 2017
End Date
October 27 2017
Last Update
August 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon
Pierre-Bénite, France, 69495